A comparative analytical investigation assessing commercial laboratory immunoassays has demonstrated that while testing platforms reliably measure serum calprotectin across normal and moderately elevated concentrations, the assays exhibit substantial inter-method divergence, pronounced proportional biases, and vulnerability to analytical hook effects at high analyte concentrations. Serum calprotectin, an abundant heterodimeric protein complex composed of S100A8 and S100A9 subunits, serves as an established circulating biomarker reflecting innate immune activation and myeloid cell turnover. In routine diagnostic settings and translational rheumatology, clinicians increasingly rely on serum calprotectin measurements to assist in evaluating systemic autoinflammatory disorders, separating active systemic autoinflammation from non-inflammatory conditions, and monitoring therapeutic responses. However, because systematic head-to-head performance evaluations of commercial systems have remained scarce, clinical laboratories lack universal reference intervals and uniform operational standards, creating critical interpretation challenges across divergent testing methodologies.
Biologically, calprotectin, also designated as myeloid-related protein 8/14 (MRP8/14), is synthesized and primarily released into circulation by activated neutrophils and monocytes during acute or chronic inflammatory cascades. Owing to its biochemical stability and high intravascular abundance during inflammatory flares, circulating calprotectin provides valuable clinical utility for assessing conditions characterized by dysregulated innate immunity, such as systemic juvenile idiopathic arthritis, adult-onset Still’s disease, familial Mediterranean fever, and pyogenic arthritis, pyoderma gangrenosum, and acne syndrome. In contrast to conventional hepatic acute-phase reactants like C-reactive protein, which is synthesized downstream by hepatocytes in response to interleukin-6 stimulation, circulating calprotectin directly mirrors myeloid lineage activation. Consequently, serum calprotectin can rise earlier or remain distinctly elevated in clinical presentations where C-reactive protein concentrations provide ambiguous diagnostic discrimination, including complex pediatric and adult cases presenting with recurrent fever of unknown origin.
To investigate analytical comparability and practical diagnostic performance, researchers examined serum specimens obtained from a cohort of forty patients diagnosed with defined autoinflammatory, infectious, or hematologic conditions alongside specimens from ten pediatric control participants. The clinical cohort comprised ten individuals with systemic juvenile idiopathic arthritis, ten with adult-onset Still’s disease, ten with familial Mediterranean fever, two with genetically confirmed PAPA syndrome, five with verified infections, and three with active leukemia. Serum specimens were retrieved from established cohorts, including the European Union Horizon 2020 ImmunAID program and university outpatient clinics, encompassing patients who had previously undergone standardized diagnostic evaluations for fever of unknown origin. The healthy pediatric control group consisted of ten children who had undergone endocrinologic assessments for growth velocity variations without presenting signs of systemic inflammation, as corroborated by normal leukocyte counts and negative C-reactive protein measurements.
The evaluation systematically compared seven commercially available immunoassay platforms spanning diverse analytical methodologies against an established internal laboratory reference comparator. The evaluated platforms included four enzyme-linked immunosorbent assays: the BÜHLMANN MRP8/14 ELISA (designated BHL EK), the Quantikine ELISA manufactured by R&D Systems, the LEGEND MAX ELISA manufactured by BioLegend, and the BMA Biomedicals MRP8/14 ELISA. The investigation also incorporated two automated particle-enhanced turbidimetric immunoassays, namely the BÜHLMANN sCAL turbo and Gentian GCAL assays run on a cobas c502 clinical analyzer, alongside one automated chemiluminescent immunoassay, the QUANTA Flash Circulating Calprotectin assay executed on a BIO-FLASH platform. For comparative benchmarking, serial extended dilutions reaching ratios as high as 1:25,000 on the BHL EK ELISA served as the primary quantitative reference comparator.
Analysis of circulating calprotectin concentrations within the healthy pediatric control cohort revealed considerable analytical baseline discrepancies among the platforms, with median control values spanning from 0.29 to 3.22 micrograms per milliliter and overall inter-assay divergence exceeding one full logarithmic order of magnitude. The BHL EK ELISA, sCAL turbo, GCAL, and QUANTA Flash systems generated quantitative healthy control measurements that aligned within manufacturer-specified normal reference intervals. In contrast, the R&D Systems and BioLegend assays yielded concentrations falling partially below their established normative ranges, whereas the BMA Biomedicals ELISA recorded control values substantially above normative thresholds. Evaluation of technical replicate precision across duplicate microplate wells demonstrated low analytical variability, with median coefficient of variation values measuring 1.9 percent for BHL EK, 1.4 percent for R&D Systems, 1.1 percent for BioLegend, and 4.8 percent for BMA Biomedicals.
Analytical recovery was further characterized across the platforms through controlled spiking experiments using purified recombinant human S100A8/A9 complex introduced into human blood type AB control serum across concentrations of 0.5, 1, 10, 50, and 100 micrograms per milliliter. Overall spike recovery rates ranged widely from 79 to 268 percent across platforms, with the sCAL turbo turbidimetric assay demonstrating the most consistent analytical recovery across the complete concentration continuum, averaging 116 percent. All evaluated assays exhibited marked overinterpretation of analyte concentrations at lower spiking ranges; at 0.5 micrograms per milliliter, calculated recoveries spanned between 180 percent for GCAL and 3154 percent for BMA Biomedicals. In addition, when isolated individual recombinant subunits were spiked independently, sCAL turbo demonstrated minor cross-reactivity with isolated uncomplexed S100A8 and S100A9 proteins, whereas combined equimolar additions of S100A8 and S100A9 were reliably measured as functional heterocomplex by sCAL turbo and GCAL.
A critical analytical finding centered on assay performance when testing specimens containing extreme calprotectin elevations exceeding 50 micrograms per milliliter, which frequently characterize severe autoinflammatory flares and reached peak observed concentrations of 1911 micrograms per milliliter in a patient with PAPA syndrome. When samples with extreme elevations were examined, several platforms failed to flag values exceeding their upper limit of detection, instead returning spuriously depressed quantitative values caused by high-dose hook effects. This artifactual suppression occurs in sandwich immunoassays when extreme antigen excess saturates immobilized capture and soluble detection antibodies simultaneously, preventing the formation of complete sandwich complexes. Consequently, the BioLegend ELISA generated false-low readouts in three of ten samples containing over 50 micrograms per milliliter at its initial 1:40 dilution, while the BMA Biomedicals ELISA produced false-low readouts in five of ten samples at 1:100 dilution. Similarly, the automated GCAL turbidimetric platform generated a false-low result for the 1911 microgram per milliliter PAPA specimen, while sCAL turbo and QUANTA Flash successfully flagged the concentration as exceeding measurement thresholds.
Statistical evaluation demonstrated strong and statistically significant rank correlation coefficients with the reference comparator across nearly all systems, yielding Spearman correlation values of r equal to or exceeding 0.96 with p values below 0.0001 for all platforms except BMA Biomedicals, which yielded an r of 0.52. Despite these robust correlation coefficients, Deming regression modeling revealed substantial proportional bias relative to the extended-dilution BHL EK reference method. Regression slopes differed markedly from unity across platforms, recording slopes of 0.49 for R&D Systems, 0.31 for BioLegend, 3.51 for BMA Biomedicals, 0.43 for sCAL turbo, 0.44 for QUANTA Flash, and 0.41 for GCAL when the false-low PAPA value was excluded. Subsequent Bland-Altman agreement analysis of log-transformed values demonstrated systematic, concentration-dependent discrepancies, confirming that absolute numerical concentrations obtained across distinct commercial platforms cannot be regarded as interchangeable in clinical practice.
Pairwise evaluations among the automated diagnostic platforms highlighted that the closest numerical concordances occurred between the sCAL turbo turbidimetric assay and the QUANTA Flash chemiluminescent system, displaying a mean bias of negative 0.038 log10 units, limits of agreement spanning negative 0.129 to positive 0.054 log10 units, and a mean quantitative concentration ratio of 0.92. When patient diagnostic subcategories involving systemic juvenile idiopathic arthritis, adult-onset Still’s disease, and familial Mediterranean fever were contrasted, median measured values showed reasonably comparable numerical bands across R&D Systems, BioLegend, sCAL turbo, GCAL, and QUANTA Flash. However, the BHL EK reference ELISA systematically generated values 2.0 to 2.5 times higher than those five platforms, while the BMA Biomedicals assay reported concentrations 3 to 6 times higher than BHL EK and 6 to 12 times higher than the remaining immunoassays.
To overcome high-dose analytical interference and suppress false-low reporting in clinical routine laboratories utilizing microplate ELISA methodologies, the investigators formulated a refined two-tier dilution workflow. Under this protocol, patient sera undergo initial testing according to standard manufacturer dilution specifications accompanied by a parallel second dilution prepared one logarithmic unit higher, such as running simultaneous 1:100 and 1:1000 dilutions. If concentration results between the dilution tiers correspond within a 20 percent deviation window or if the primary dilution yields a higher concentration than the secondary dilution, the primary calculated result is verified. Conversely, if results diverge by more than 20 percent with the higher dilution demonstrating elevated back-calculated concentrations, laboratories must execute further tertiary dilutions to accurately resolve true concentrations without hook-effect suppression. Automated turbidimetric and chemiluminescent analyzers mitigate this vulnerability through programmed automatic reflex dilution pathways upon encountering initial absorption or luminescence limits.
The study authors contextualized these technical findings within broader clinical implementation pathways, noting that circulating calprotectin has achieved technology readiness level 7 as an operational biomarker implemented within institutional central laboratories for guiding inpatient and outpatient care. The clinical utility of routine serum calprotectin testing encompasses tracking disease quiescence, differentiating autoinflammatory conditions from masquerading infectious syndromes, and monitoring therapeutic responses to biologic agents targeting interleukin-1 or interleukin-6 pathways. Nevertheless, analytical pitfalls underscore that unexpected normal or mildly elevated calprotectin measurements in patients presenting with high clinical suspicion of severe autoinflammation require direct communication between attending physicians and laboratory specialists to prompt manual reflex dilution and rule out hook-effect underestimation.
The researchers noted essential methodological limitations in their comparative evaluation, including the omission of certain commercial assay kits available on the international market and restricted patient serum volumes that reduced the total number of control samples analyzed on the BMA Biomedicals and QUANTA Flash platforms. Furthermore, the deliberate assembly of a heterogeneous patient cohort across wide clinical spectrums yielded modest subgroup sample sizes, precluding the statistical calculation of definitive diagnostic cut-off thresholds for individual autoinflammatory conditions. In conclusion, while commercial serum calprotectin immunoassays provide valuable diagnostic insight into innate immune activation, their lack of interchangeability necessitates assay-specific reference intervals, robust laboratory dilution protocols, and international calibration standardization to ensure safe diagnostic application.
Subject of Research: Comparative analytical evaluation of commercial serum calprotectin immunoassays in autoinflammatory diseases
Article Title: Challenges in measuring serum calprotectin in autoinflammation: a comparative study of different immunoassays
Article References: Wittkowski, H., Park, C., Saers, M., Fühner, S., Schleifenbaum, S., Hinze, C., Fobker, M., Karolin, A., Horn, M. P., Schlüter, B., & Foell, D. (2026). Challenges in measuring serum calprotectin in autoinflammation: a comparative study of different immunoassays. Molecular and Cellular Pediatrics, 13(1), Article 54. https://doi.org/10.1186/s40348-026-00267-8
Image Credits: AI Generated
DOI: 10.1186/s40348-026-00267-8
Keywords: serum calprotectin, S100A8/A9 complex, autoinflammatory diseases, systemic juvenile idiopathic arthritis, adult-onset Still’s disease, familial Mediterranean fever, PAPA syndrome, immunoassay comparison, enzyme-linked immunosorbent assay, particle-enhanced turbidimetric immunoassay, chemiluminescent immunoassay, high-dose hook effect, biomarker standardization, inter-assay variability, dilution protocol, Deming regression, Bland-Altman analysis
